Success for rheumatoid arthritis drug study

(iStock)

Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.

"We are now investigating the various possibilities through which we can progress the development of ALX-0061, including discussions with potential partners and other paths which will allow us to maximise the value of this asset," Chief Executive Edwin Moses said in a statement on Wednesday.

Ablynx had carried out the study on 37 patients over the course of 24 weeks and said the drug was well-tolerated and showed positive results.